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A B S T R A C T
Biomarkers for neurodegenerative dementias oﬀer interesting prospects regarding diagnosis and disease mon-
itoring. Monoamines such as dopamine, (nor)adrenaline, serotonin (5-hydroxytryptamine or 5-HT), and their
respective metabolites homovanillic acid (HVA) and 3,4-dihydroxyphenylacetic acid, 3-methoxy-4-hydro-
xyphenylglycol (MHPG), and 5-hydroxyindoleacetic acid (5-HIAA), were shown to be altered in dementia, in-
cluding Alzheimer's disease (AD). Biomarker research is hampered by potential confounds including the inﬂu-
ence of time of day and volume of cerebrospinal ﬂuid (CSF) collected. Therefore, the possibility of a circadian
rhythm in CSF and plasma, and the presence of a rostrocaudal concentration gradient (RCG) in CSF for afore-
mentioned monoamines/metabolites, were investigated.
Circadian rhythmicity was assessed using reversed-phase ultra-high performance liquid chromatography with
electrochemical detection (RP-UHPLC-ECD) to measure monoamine/metabolite concentrations in 271 paired
CSF and plasma samples, successively collected over a period of 30 h and derived from eight healthy subjects.
Plasma samples were also analyzed for melatonin, serving as positive control analyte, using ELISA. The RCG
examination entailed RP-UHPLC-ECD analyses on ﬁve consecutive CSF samples derived from 10 patients with
AD and 10 non-AD/control subjects.
Besides a diurnal rhythm for melatonin, we found a similar rhythmicity for plasma HVA, with acrophases
occurring between 02:00 and 06:00 h, in four out of seven subjects. Three and two subjects showed a circadian
rhythm for CSF HVA and 5-HIAA, respectively. No rhythmicity was observed in any other compound. We found
that only CSF MHPG, HVA and 5-HIAA levels diﬀered across CSF fractions, and that these changes in 5-HIAA
levels varied in the AD versus non-AD/control group. Positive correlations between CSF volume and HVA and 5-
HIAA levels, indicative of a RCG, were also observed. Such a RCG could not be detected for the other mono-
amines/metabolites. Our results stress the importance of standardizing sampling procedures of biological ﬂuids
with respect to time of day, volume and number of samples.
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1.1. Monoamines as biomarkers for neurodegenerative dementias
Cerebrospinal ﬂuid (CSF)- and blood-based biomarkers represent
interesting opportunities for the diﬀerential diagnosis of neurodegen-
erative dementias (Lewczuk et al., 2018). For example, amyloid beta
peptide of 42 amino acids (Aβ1-42), total tau (T-tau) and tau phos-
phorylated at threonine 181 (P-Tau181P) are widely known as the
standard CSF biomarker panel to aid in the diﬀerential diagnosis of
Alzheimer's disease (AD) (Dubois et al., 2014; Simonsen et al., 2017).
Besides their application in diagnostic evaluation, biomarkers are im-
plemented in other contexts of use, such as disease- and treatment re-
sponse monitoring (Zverova, 2018). In this aspect, blood-based bio-
markers are preferred over CSF markers given the relative invasiveness
and practical disadvantages inherent to a lumbar puncture (LP)
(Humpel, 2011; Zverova, 2018). Nevertheless, a suitable blood bio-
marker for AD diagnosis or disease monitoring, is still lacking. Some
promising candidate molecules (plasma T-tau and serum neuroﬁlament
light chain) have already been identiﬁed (reviewed by Keshavan et al.,
2017), but still face several challenges, among which are a lack of re-
producibility (O'Bryant et al., 2017; Shi et al., 2018).
In addition, despite their usefulness for the diagnosis of AD, CSF
Aβ1-42, T-tau and P-Tau181P were proven to have little eﬃcacy in di-
agnosing dementias other than AD (De Deyn, 2015; Engelborghs et al.,
2008; Niemantsverdriet et al., 2015, 2017). However, distinct dementia
types were previously hypothesized to have dissimilar neurochemical
underpinnings with regard to monoamine content in the central ner-
vous system, including dopamine (DA), (nor)adrenaline ((N)A), and
serotonin or 5-hydroxytryptamine (5-HT), and their respective meta-
bolites, i.e. 3,4-dihydroxyphenylacetic acid (DOPAC) and homovanillic
acid (HVA), 3-methoxy-4-hydroxyphenylglycol (MHPG), and, 5-hy-
droxyindoleacetic acid (5-HIAA) (Vermeiren et al., 2016). Studies in-
vestigating brain areas of patients suﬀering from AD, frontotemporal
dementia (FTD) and dementia with Lewy bodies (DLB) support this
theory (Vermeiren et al., 2015, 2016). These dissimilarities in mono-
aminergic compounds between AD and other dementias, have also been
identiﬁed in CSF and serum (Aerts et al., 2011; Herbert et al., 2014;
Janssens et al., 2018; Parnetti et al., 1992; Sjögren et al., 1998). For
instance, the addition of CSF (and serum) MHPG - the major metabolite
of (N)A indicating noradrenergic turnover (Chase et al., 1973) - to the
standard CSF biomarker panel for AD, improved the ability of the panel
to diﬀerentiate AD and DLB (Herbert et al., 2014; Janssens et al., 2018).
Taken together, monoamines and/or their metabolites in CSF and blood
are potentially of added value as diagnostic biomarkers for dementia,
whether they are combined with a previously validated biomarker
panel, or implemented as stand-alone compounds (Janssens et al.,
2018).
1.2. Diﬃculties associated with sampling of CSF and plasma biomarkers
One of the diﬃculties concerning biomarker research, is the lack of
reproducibility across laboratories (Lewczuk et al., 2018). The pre-
analytical phase, comprising sample collection, -handling, -transport,
and -storage, is reported to be speciﬁcally prone to errors, accounting
for up to 70% of all mistakes in laboratory diagnostics (Lippi et al.,
2011; Plebani and Carraro, 1997), and possibly impacting the quality of
biomarker assessment (Lewczuk et al., 2018). Eﬀorts should be made to
develop a standardized and holistic approach covering the use of cor-
rect laboratory equipment, sampling and storage volume, appropriate
temperature for transport and storage, centrifugation settings and
fasting status of study participants (Lewczuk et al., 2018; Lippi et al.,
2011; O'Bryant et al., 2015; Shi et al., 2018).
Another possible source of variability between the ﬁndings of dif-
ferent groups is the potential inﬂuence of time of day and volume of
CSF aspirated. This work will primarily focus on sampling time, with
respect to the circadian rhythm of monoamines and/or their metabo-
lites in CSF and plasma, and the presence of a possible rostrocaudal
concentration gradient (RCG) of these compounds in CSF.
1.2.1. Circadian rhythm of monoaminergic compounds in CSF and plasma
While some studies suggest the existence of a physiological circa-
dian rhythm of CSF Aβ levels (Bateman et al., 2007; Bjerke et al., 2010;
Huang et al., 2012), little evidence exists concerning possible circadian
ﬂuctuations of monoaminergic compounds in human (patho)phy-
siology. Dopaminergic compounds, including DA and HVA, were found
to ﬂuctuate diurnally in the CSF of patients suﬀering from Parkinson's
disease, restless legs syndrome and control subjects (Poceta et al.,
2009). Alternatively, a circadian rhythm for 5-HT was reported in
serum derived from healthy and schizophrenic subjects (Rao et al.,
1994), as well as in whole blood samples of controls and depressed
patients (Pietraszek et al., 1991). The main metabolite of 5-HT, 5-HIAA,
was also shown to have a circadian rhythm contrary to that of its
precursor in whole blood (Pietraszek et al., 1991). Diurnal ﬂuctuations
of plasma and serum (N)A have also been reported (Linsell et al., 1985;
Rao et al., 1995), although other studies found an ultradian rhythm in
the noradrenergic neurotransmitter system, consisting of 20–30 pulses
of (N)A per 24 h (hrs), depending on the analysis software (Schöﬂ et al.,
1997). Finally, concentrations of plasma MHPG were also shown to
vary diurnally in six control subjects (DeMet et al., 1985). These ﬁnd-
ings could also be corroborated by a later study investigating plasma
MHPG levels in healthy volunteers as well as in patients suﬀering from
depression (Gwirtsman et al., 1989).
1.2.2. Rostrocaudal concentration gradient
Whereas limited evidence exists concerning diurnal rhythms of
monoamines/metabolites in biological ﬂuids, state of the art evidence
generally agrees on the existence of a RCG for CSF HVA and 5-HIAA. A
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subjects as well as in patients suﬀering from neuropsychiatric diseases,
such as vascular dementia, mixed dementia, organic depression and
psychosis, which did not aﬀect CSF circulation. In contrast, MHPG le-
vels did not show any variation in consecutive CSF samples (Blennow
et al., 1993). Similar ﬁndings were reported in a study analyzing
monoaminergic metabolites in CSF derived from children and adoles-
cents aged 6.50–17.25 years with obsessive-compulsive disorder and/or
attention deﬁcit disorder (Kruesi et al., 1988). In addition, levels of
HVA and 5-HIAA in consecutive CSF fractions derived from patients
with (possible) hydrocephalus also rose with increasing sampling vo-
lume in two separate studies (Malm et al., 1994; Sjöström et al., 1975).
Concentrations of MHPG were previously reported to be comparable
across CSF fractions (Kruesi et al., 1988; Sjöström et al., 1975), al-
though another study reported increased MHPG levels with increasing
CSF sampling volume (Ziegler et al., 1977). However, current literature
provides little support for a RCG in levels of monoamine neuro-
transmitters. Most of the aforementioned studies also date from two
decades ago, and analytical research methods have improved ever
since.
1.3. Aims and hypothesis
The aim of this work is to elaborate on the presence of a possible
circadian rhythm in plasma and CSF monoamines and their metabolites
to establish an optimal sampling time of these biological ﬂuids. We
included plasma melatonin as a positive control analyte, given the ex-
tensive evidence of its circadian rhythm (Cajochen et al., 2003; Zeitzer
et al., 2007; Zhdanova et al., 1998; Zisapel, 2018). Based on the
available literature, we expected to ﬁnd a circadian rhythm in plasma
and CSF for 5-HT and 5-HIAA in particular, since these compounds are
closely related to melatonin. In addition, we intended to provide evi-
dence for a RCG of monoamine neurotransmitters and their metabo-
lites, with special regard to HVA and 5-HIAA.
2. Materials & methods
2.1. Study population
The inclusion procedure for the study of circadian rhythm has been
described in detail in previous work (den Daas et al., 2013; Naude et al.,
2017). In short, eight healthy males aged 50–75 were enrolled, of
whom seven completed the entire protocol. The exclusion parameters
for this study entailed a body mass index> 27 kgm−2, body
weight> 100 kg, acute cellulitis, onychomycosis of the feet, increased
white blood cell count, poor venous access, history of lower back pain,
signiﬁcant kyphosis and/or scoliosis or other spinal column defor-
mities, persisting ﬁbromyalgia, a history of diﬃcult LP, a history of
and/or any sign or symptom indicating abnormal hemostasis or blood
dyscrasia and any disorder which could lead to increased intracranial
pressure, such as glaucoma or hydrocephalus-related pathology. Elderly
men were chosen since they have lower intradural cavity pressure and
thus have a reduced likelihood of CSF leakage and post dural puncture
headache. After a screening period, the subjects arrived at the clinic on
day −2. During the next day (day −1), the volunteers received 2 L of
0.9% saline solution by intravenous infusion. On day 1, intradural ca-
theterization was performed under strict aseptic conditions by an
experienced anesthesiologist. At 12 h and 36 h after intradural cathe-
terization, the subjects received fraxiparine for antithrombotic pro-
phylaxis. During this period, subjects were allowed to move around
freely and samples of 2mL each were collected in 5mL polypropylene
tubes by interval sampling over a 30-h period starting at 10:00 h (t= 1)
of day 1 (Fig. 1). Samples were withdrawn at hourly intervals by as-
piration with a syringe during the ﬁrst 12 h, at four-hour intervals be-
tween sampling times 13 and 16, and, ﬁnally, at two-hour intervals
from sampling time 16 until 19 (Fig. 1). This led to a total of 19 paired
CSF and plasma serial samples per subject, resulting in a total of 271
CSF and plasma samples. This study was approved by the local medical
ethics committee (Stichting Beoordeling Ethiek Bio-Medisch Onder-
zoek, Assen, the Netherlands) and conducted in compliance with the
Helsinki declaration and the Guideline for Good Clinical practice.
For investigation of the RCG, 10 probable AD patients and 10
probable non-AD/control subjects were included via a study protocol
concerning CSF biomarkers of dementia (Vermeiren et al., 2013). The
diagnosis of probable AD was routinely made according to the revised
criteria of the National Institute of Neurological and Communicative
Disorders and Stroke-Alzheimer's Disease and Related Disorders Asso-
ciation (NINCDS-ADRDA) (McKhann et al., 2011). Additionally, all AD
patients fulﬁlled the criteria of the Diagnostic and Statistical Manual of
Mental Disorders, 4th edition (DSM-IV-TR) (American Psychiatric
Association, 2000). The clinically diagnosed AD patients underwent a
LP and neurocognitive assessment including the Mini-Mental State
Examination (Folstein et al., 1983) as part of their diagnostic work-up
of probable dementia. In addition, an AD-speciﬁc, pathological CSF
biomarker proﬁle was determined in these patients shortly thereafter
(i.e. CSF levels of Aβ1-42< 638.5 pg/mL, T-tau> 296.5 pg/mL, and P-
tau181P > 56.5 pg/mL (Engelborghs et al., 2008). Similarly, age- and
gender-matched individuals who had subjective memory complaints
and/or were referred to a neurologist on the suspicion of dementia,
underwent LP and neurocognitive assessment. Although these 10 sub-
jects had normal, physiological biomarker proﬁles, a non-AD dementia
diagnosis could not be fully excluded solely based upon the measured
Aβ1-42, T-tau and P-tau181P levels. All included subjects were recruited
at the Memory Clinic of the Hospital Network Antwerp Middelheim
(ZNA) and Hoge Beuken (Antwerp, Belgium). According to the afore-
mentioned protocol, ﬁve consecutive fractions of CSF were collected
from both the non-AD/control and AD groups (Vermeiren et al., 2013).
Lumbar puncture was performed at the L3/L4 or L4/L5 interspace be-
tween 08:00 and 10:00 h, after fasting and abstention from smoking for
at least 12 h. Approximately 16.5mL of CSF was collected in an ordered
manner: C1 (4.5 mL), C2 (1.5 mL), C3 (1.5 mL), C4 (4.5 mL) and C5
(4.5mL) fractions were sampled in polypropylene vials (Nalgene; VWR,
Leuven, Belgium), making up a total of 100 samples for the RCG ana-
lysis of CFS monoamines. Samples were placed in liquid nitrogen im-
mediately after LP, and stored at −80 °C until neurochemical analysis.
For routine AD CSF biomarker analyses, the C2 fraction was used.
Biomarkers were measured via single analyte ELISA-kits (INNOTEST,
Fujirebio, Ghent, Belgium).
2.2. RP-UHPLC-ECD
The quantiﬁcation of CSF and plasma monoamines and their cor-
responding metabolites was performed using an optimized Alexys
Fig. 1. Time schedule of CSF and plasma sampling. Sampling started at 10:00 h on day 1, and lasted until 16:00 h on day 2. During the ﬁrst 12 h, CSF and plasma
were collected hourly, followed by three four-hour sampling intervals. For the last six hours of the protocol, samples were taken every two hrs. Abbreviations: CSF:
cerebrospinal ﬂuid; hrs: hours.
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Neurotransmitter Analyzer with electrochemical detection (ECD)
(Antec Leyden BV, Zoeterwoude, the Netherlands). This reversed-phase
ultra-high performance liquid chromatography (RP-UHPLC) system
operated at an isocratic ﬂow rate of 75 μL/min. The Decade II elec-
trochemical detector was equipped with a thin layered electrochemical
VT03 ﬂow cell ﬁtted with a glassy carbon 0.7mm working electrode
and an in situ Ag/AgCl (ISAAC) reference electrode. Integration of
chromatograms was performed with channel integration M018/EN25B
Clarity software (DataApex Ltd., Prague, The Czech Republic, version
6.2). The mobile phase consisted of 11% methanol combined with citric
acid (100mM), phosphoric acid (100mM), octane-1-sulfonic acid so-
dium salt (2.8 mM), KCl (8 mM), and, ethylenediaminetetraacetic acid
(0.1 mM). The pH of the mobile phase was set at 3.0. Samples of 5 μL
were loaded with an Alexys AS 110 Autosampler. Separation was
achieved using a short 15 cm Waters Acquity Column (BEH C18, 1mm
diameter, particle size 1.7 μm), delivering optimal performances for
monoamine analysis. Total runtime for each sample was under 15min,
after which all eight monoamines and metabolites were detected. With
respect to the sample preparation protocol, Amicon Ultracentrifugal
ﬁlters (3000 Da; Millipore, Ireland) were washed twice by centrifuga-
tion of 450 μL of sample preparation buﬀer at 14,000×g for 25min at
4 °C. Next, 400 μL of plasma or CSF was directly transferred to the
washed Amicon ﬁlters and centrifuged at 14,000×g for 40min, still at
4 °C. After centrifugation, one fraction of the eluate was diluted 1:4 and
injected in the RP-UHPLC-ECD system in the case of both CSF and
plasma, while a second 1:20 plasma dilution was also analyzed.
2.3. ELISA
Enzyme-linked immunosorbent assay (ELISA) kits were used ac-
cording to the manufacturer's instructions (RE54021; IBL. International
GMBH, Hamburg, Germany) to determine plasma melatonin levels.
2.4. Statistics
For the analysis of circadian rhythm, mixed linear model analysis
implementing compound symmetry covariance structure with hetero-
geneous variances, was performed on log-transformed plasma mela-
tonin and plasma/CSF monoamine concentrations. Parameter
Table 1
Demographics of the subjects included for the study of cir-
cadian rhythm. Data are represented as median, with the IQR
denoted between brackets. Abbreviations: BMI: body mass
index; IQR: interquartile range.
Parameter
Age (years) 62.5 (8.3)
Gender (male/female) 8/0
Weight (kg) 79.4 (9.5)
Height (cm) 179.0 (16.3)
BMI (kg/m2) 24.3 (2.6)
Fig. 2. Plasma melatonin and HVA concentrations, as well as CSF HVA and 5-HIAA levels, as a function of sampling time (panels A, B, C, and D respectively). The
range of statistically signiﬁcant acrophases for each compound, is indicated in grey. A: The plasma melatonin concentration at time point 14 diﬀered signiﬁcantly
compared to almost all other time points. B: The acrophase of plasma HVA is situated in a similar time frame compared to melatonin. C, D: CSF HVA and 5-HIAA
levels did not show a clear diurnal rhythm, and were characterized by a rather high variability. Abbreviations: 5-HIAA: 5-hydroxyindoleacetic acid; CSF: cere-
brospinal ﬂuid; HVA: homovanillic acid.
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estimation for these models was obtained implementing the restricted
maximum likelihood method. In case a statistically signiﬁcant eﬀect of
time was detected, post-hoc analysis consisted of pairwise comparisons
based on the least-squares means, with Bonferroni-adjusted p-values
(statistically signiﬁcant if P < 0.05). In addition, single cosinor ana-
lysis was applied to estimate the acrophase, amplitude and midline
estimating statistic of rhythm (MESOR) of circadian rhythms displayed
by melatonin and monoaminergic compounds. For the investigation of
the RCG in CSF monoamines and/or metabolites, the independent-
samples T-test and chi-square statistics were applied to verify if AD- and
non-AD/CONTR groups were age- and gender-matched, respectively. In
addition, mixed factorial ANOVA with CSF fraction as within-subjects
variable and diagnostic class as between-subjects factor, was used to
analyze the eﬀects of the possible RCG and/or disease status on CSF
monoamine/metabolite levels. In case the assumption of sphericity was
violated, the Greenhouse-Geisser correction was applied. Post-hoc
pairwise comparisons based on the estimated marginal means were
performed to detect diﬀerences in monoamine/metabolite levels be-
tween CSF fractions. Again, p-values were adjusted according to the
Bonferroni correction for multiple comparisons. Finally, the correlation
between withdrawn CSF volume and concentrations of monoaminergic
compounds was tested using Spearman's correlation statistics. All sta-
tistical analyses, except for cosinor analysis, were performed using SPSS
24.0 for Windows (IBM SPSS Software, Armonk, NY, IBM Corp.).
Cosinor models were ﬁtted using the cosinor package in R (Sachs,
2014), version 3.4.0 for Windows, while the zero-amplitude test for the
detection of a statistically signiﬁcant rhythm was performed using the
cosinor2 package (Mutak, 2017). Figures were produced using
GraphPad Prism version 6.0 for Windows (GraphPad Software, La Jolla
California USA, www.graphpad.com).
3. Results
3.1. Demography – circadian rhythm
The demographic characteristics of subjects included for the study
of circadian rhythm, are summarized in Table 1. Plasma and CSF
samples were stored at−70 °C within 30min after sampling, and were
thawed twice beforehand to facilitate assays for other substances (den
Daas et al., 2013).
3.2. Mixed linear model analysis to detect concentration changes over time
The concentration changes of plasma melatonin and CSF and plasma
HVA over time, are depicted in Fig. 2. Mixed linear model analysis on
log-transformed melatonin values indicated a statistically signiﬁcant
eﬀect of sampling time (F (18, 24.79)= 3.61; P < 0.05), with pro-
nounced post-hoc diﬀerences between time point 14 of sampling, cor-
responding to 02:00 h, and almost all other time points (Table 2). In
addition, log-transformed HVA concentrations in CSF (F (18,
23.39)= 5.16; P≤ 0.001), as well as in plasma (F (18, 17.34)= 2.58;
P < 0.05), varied signiﬁcantly across time points. No diﬀerences could
be detected in plasma HVA levels after correcting for multiple com-
parisons. As for log-transformed 5-HIAA levels in CSF, a signiﬁcant
eﬀect of sampling time was also found (F (18, 21.61)= 2.15;
P < 0.05), although only diﬀerences between the second and 17th, as
well as between the second and 19th time points remained signiﬁcant
after Bonferroni correction (Table 2). Finally, a statistically signiﬁcant
diﬀerence across sampling times was detected for log-transformed
plasma DOPAC levels (F (18, 14.30)= 2.48; P < 0.05), although only
the pairwise comparison between the 17th and 18th time point re-
mained signiﬁcant after the post-hoc analysis. Statistically signiﬁcant
post-hoc diﬀerences in monoaminergic metabolite concentrations are
summarized in Table 2, and raw data representing the mean con-
centrations at each signiﬁcant time point, are represented in
Supplementary Table 1.
3.3. Circadian rhythm analysis
A statistically signiﬁcant diurnal rhythm could be corroborated for
plasma melatonin in ﬁve out of seven subjects, while four out of seven
subjects showed such a rhythmicity for plasma HVA. All estimated
parameters and statistics for plasma melatonin and HVA in each subject
are represented in Supplementary Table 2. The acrophase of plasma
melatonin, indicating the time at which its concentrations were highest,
was at night, ranging from about 02:00 to 05:30 h and corresponding to
sampling point 14, for which most of the pairwise diﬀerences were
found (Fig. 2, panel A; Table 2). A clear surge of plasma melatonin
levels can indeed be observed at sampling time 14, followed by a rapid
decrease of melatonin concentration. For two out of seven subjects, the
assumption of normality of residuals was violated. In case of plasma
HVA, four out of seven subjects showed a statistically signiﬁcant
diurnal rhythm, of which the acrophase ranged from about 01:00 to
04:30 h. Here, a more steady rise and decrease in analyte concentra-
tions was observed (Fig. 2, panel B). However, the assumption of nor-
mality was not met for three individuals. No circadian rhythm could be
observed in plasma DOPAC concentrations. Remarkably, a larger
variability in CSF analyte levels was generally observed compared to
plasma. Two out of seven subjects also showed a signiﬁcant rhythm for
CSF HVA, with peak levels at 04:53 h, while the acrophase of the third
individual with a signiﬁcant rhythmicity, was at around 20:00 h (Fig. 2,
panel C). In addition, CSF HVA data of two subjects did not comply with
the assumption of independence of residuals. Our results also indicated
a 24-h rhythm in CSF 5-HIAA levels in two out of seven subjects, with
acrophases ranging from 20:36–04:09 h (Fig. 2, panel D). Lastly, data of
four subjects did not comply with the assumption of independent ob-
servations, and an additional non-normal distribution of CSF 5-HIAA
levels was found in two of these four participants.
Table 2
Pairwise comparisons between sampling times of melatonin or monoaminergic
compounds in CSF or plasma. Melatonin, HVA, 5-HIAA and DOPAC con-
centrations were log-transformed to fulﬁll the assumption of normality of re-
siduals. Only statistically signiﬁcant diﬀerences after post-hoc Bonferroni cor-
rection (P < 0.05) are displayed. Abbreviations: 5-HIAA: 5-




Mean diﬀerence ± SE p-value
Plasma Melatonin
(Log(pg/mL))
2–14 −0.404 ± 0.089 0.036
3–14 −0.508 ± 0.090 0.004
4–14 −0.486 ± 0.072 0.001
5–14 −0.438 ± 0.085 0.006
6–14 −0.491 ± 0.096 0.005
7–14 −0.569 ± 0.107 0.002
8–14 −0.504 ± 0.121 0.031
9–14 −0.500 ± 0.083 0.001
10–14 −0.524 ± 0.101 0.003
11–14 −0.548 ± 0.103 0.002
14–17 0.423 ± 0.100 0.036
14–18 0.415 ± 0.090 0.017
14–19 0.479 ± 0.093 0.004
CSF HVA (Log(ng/
mL))
2–10 −0.164 ± 0.036 0.044
2–12 −0.205 ± 0.035 0.003
2–17 −0.179 ± 0.037 0.006
2–19 −0.208 ± 0.035 0.004
3–12 −0.143 ± 0.029 0.005
3–18 −0.116 ± 0.026 0.024
3–19 −0.146 ± 0.028 0.002
CSF 5-HIAA (Log(ng/
mL))
2–17 −0.172 ± 0.040 0.044
2–19 −0.179 ± 0.040 0.030
Plasma DOPAC (Log
(ng/mL))
17–18 0.129 ± 0.026 0.027
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3.4. Demography – rostrocaudal concentration gradient
The study population consisted of age- and gender matched in-
dividuals in both non-AD/CONTR (n= 10) and AD (n=10) groups.
Demographic parameters are summarized in Table 3.
3.5. Mixed model ANOVA
Mixed model ANOVA was performed to verify eﬀects of a possible
RCG and diagnostic category on a subset of metabolite levels, as (N)A,
DA, 5-HT and DOPAC could not be reliably detected in these CSF
samples. A signiﬁcant eﬀect of CSF fraction was found for MHPG (F
(2.66, 47.88)= 8.67; P < 0.001), while the eﬀect of CSF fraction was
not diﬀerent between diagnostic classes (F (2.66, 47.88)= 1.52;
P > 0.05). Likewise, HVA levels were found to diﬀer across CSF frac-
tions (F (2.32, 41.71)= 29.85; P < 0.001), without a signiﬁcant in-
teraction eﬀect between diagnostic class and CSF subsample (F (2.32,
41.71)= 2.96; P > 0.05). A statistically signiﬁcant eﬀect of CSF
fraction on 5-HIAA levels was also detected (F (2.56, 45.99)= 24.97;
P < 0.001). Moreover, the behavior of the RCG was diﬀerent in each
diagnostic class, indicated by a signiﬁcant interaction eﬀect (F (2.56,
45.99)= 3.81; P < 0.05). The levels of monoamine metabolites in
each subfraction and post-hoc diﬀerences, are displayed in Table 3. No
global upward trend could be observed for CSF MHPG levels (Fig. 3,
panel A), while diminished levels were noted in the C2 and C4 fraction.
In addition, a similar pattern was detected for CSF HVA and 5-HIAA
levels (Fig. 3, panel B and C, respectively), characterized by a general
increase with collected CSF volume. A drop in both analyte levels could
also be recognized in the C4 subsample. Lastly, markedly higher CSF 5-
HIAA concentrations were observed in the AD group compared to non-
AD/control individuals.
3.6. Correlation between metabolite concentrations and CSF fraction
Spearman's correlation statistics showed that both CSF HVA (rs
(18)= 0.221; P < 0.05) and 5-HIAA (rs(18)= 0.213; P < 0.05) le-
vels increased with collected CSF volume, whereas no association was
found between MHPG levels and CSF fraction (rs(18)= 0.043;
P > 0.05). As CSF fraction impacted CSF 5-HIAA levels diﬀerently in
the non-AD/CONTR group compared to the AD group, we also in-
vestigated whether diﬀerent correlations could be found in those two
diagnostic categories. However, no statistically signiﬁcant association
was found between CSF 5-HIAA levels and CSF fraction when non-AD/
CONTR (rs(8)= 0.211; P > 0.05) and AD (rs(8)= 0.254; P > 0.05)
groups were analyzed separately.
4. Discussion
4.1. Circadian rhythm of melatonin and monoamines
Regarding circadian rhythm analyses in CSF, mainly negative re-
sults were found. Indeed, previous reports indicate the absence of
diurnal rhythmicity in CSF DOPAC (Poceta et al., 2009) and MHPG,
albeit in non-human primates (Perlow et al., 1978). Concentrations of
CSF HVA and 5-HIAA did show a 24-h rhythm, although only in three
and two subjects, respectively. Moreover, the acrophases of these
rhythms showed a large variability, causing these results to remain
inconclusive. Five and four out of the seven subjects who completed the
protocol, showed a statistically signiﬁcant circadian rhythm for plasma
melatonin and HVA, respectively, which might be due to the non-
normal distribution of these analyte concentrations. In addition, it is
possible that the sleep-wake cycle of those two and three subjects was
disturbed as a consequence of the hospital setting. Interestingly, the
acrophases of melatonin and HVA, either in plasma or CSF, were si-
tuated in a similar time frame (01:00–06:00 h). This might be explained
by the fact that both melatonin and DA are regulated by the major
circadian pacemaker in the hypothalamus, the suprachiasmatic nucleus
(SCN) (Mendoza and Challet, 2014; Reiter, 1991; Sleipness et al., 2007;
Zisapel, 2018). Brieﬂy, the SCN regulates melatonin synthesis in the
pineal gland via stimulatory and inhibitory stimuli, highly dependent
on the light signal received from the retina (Kalsbeek et al., 2000;
Perreau-Lenz et al., 2004). Dopaminergic activity is also hypothesized
to be organized by the SCN. As an example, behavioral and neuro-
chemical disturbances were observed in mice lacking Rev-erbα, a nu-
clear receptor involved in the feedforward loop of the molecular
clockwork of circadian rhythm (Preitner et al., 2002). These mice ex-
hibited increased production of tyrosine hydroxylase (TH), the rate-
limiting enzyme in DA synthesis (Molinoﬀ and Axelrod, 1971), and
increased DA turnover, indicated by a surge in HVA/DA ratios (Jager
et al., 2014). In addition, protein levels of TH and DA transporters have
been reported to be higher at night in the nucleus accumbens of male
Sprague-Dawley rats (Sleipness et al., 2007), coinciding with our
ﬁndings of peak HVA levels in both plasma and CSF at night. However,
it should be noted that the evidence for dopaminergic regulation by the
SCN was mainly raised in a preclinical setting, which might complicate
a straightforward comparison with the results of this work. Our hy-
pothesis stated that a circadian rhythm would be expected in the ser-
otonergic system, as this is closely related to melatonin. However, no
such diurnal variation was observed in these compounds, except for CSF
5-HIAA in only two out of seven participants. The relatively high
variability of our measurements in combination with a small sample
size, might account for these negative results.
We are also aware of the possible confounding inﬂuence of diet on
monoaminergic content (Wurtman and Fernstrom, 1975), with high-
carbohydrate meals causing increased tryptophan and 5-HT contents in
Table 3
Demographic and biochemical parameters of subjects included in the RCG
study. All data are presented as mean ± SD. Signiﬁcant diﬀerences after post-
hoc correction for multiple comparisons (P < 0.05) are indicated by super-
script letters a, b, c, d, e, f, g, h, i, and j for diﬀerences between C1 and C2, C1
and C3, C1 and C4, C1 and C5, C2 and C3, C2 and C4, C2 and C5, C3 and C4, C3
and C5, and, C4 and C5, respectively. Statistically signiﬁcant diﬀerences after
independent samples T-tests between the non-AD/CONTR and the AD group, or
mixed model ANOVA, are depicted in the rightmost column. In case of 5-HIAA,
the eﬀect of CSF subsample is ﬁrst represented, followed by the statistical
signiﬁcance of the interaction between CSF fraction and diagnostic class.
Abbreviations: 5-HIAA: 5-hydroxyindoleacetic acid; AD: Alzheimer's disease;
C1-5: ﬁve consecutive CSF fractions containing 4.5 mL, 1.5 mL, 1.5 mL, 4.5 mL
and 4.5mL, respectively; CONTR: control; CSF: cerebrospinal ﬂuid; HVA:
homovanillic acid; MHPG: 3-methoxy-4-hydroxyphenylglycol; RCG: ros-
trocaudal concentration gradient.
Parameter Non-AD/CONTR AD Test statistic












C1 23.8 ± 11.5a F (2.66,
47.88)=8.67
P < 0.001
C2 19.1 ± 9.3a,e,g
C3 24.8 ± 12.0e
C4 22.0 ± 10.5
C5 23.9 ± 11.2g
CSF HVA (ng/
mL)
C1 30.8 ± 13.9a,b,c,d F (2.32,
41.71)=29.85
P < 0.001
C2 37.5 ± 16.4a,g
C3 38.0 ± 15.9b,i
C4 35.2 ± 15.0c,j
C5 44.3 ± 18.9d,g,i,j
CSF 5-HIAA
(ng/mL)






C2 15.0 ± 5.8 23.9 ± 11.3a,g
C3 15.3 ± 5.1 24.5 ± 11.4b,i
C4 13.9 ± 4.7j 23.0 ± 9.0c,j
C5 16.8 ± 4.7j 28.8 ± 10.2d,e,f,j
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the brain. In addition, levels of DA and (N)A increase in response to
meals consisting of 40% protein. Since we did not measure brain
monoamine levels and since we only found evidence of a circadian
rhythm in metabolites of these compounds, it is diﬃcult to determine
whether food consumption aﬀected our ﬁndings. Nevertheless, the
observed similarities in circadian rhythm of melatonin, a metabolite of
5-HT, and HVA, are not entirely consistent with a dietary inﬂuence on
these molecules. Since subjects participating in this study received
standardized meals mainly consisting of carbohydrates, the increase in
melatonin could be foreseen. The surge of HVA at the same time point,
however, is contradictory with the eﬀect of high-carbohydrate meals. In
addition, three surges in melatonin, one after each meal of the day,
would also be expected if diet had truly inﬂuenced our observations.
Altogether, we propose to sample plasma and CSF at standardized
times when the variation in monoamine/metabolite levels is lowest.
According to our results, this would be in the early afternoon
(12:00–15:00 h).
4.2. Rostrocaudal concentration gradient
As expected from previous reports, no RCG was observed for CSF
MHPG, while HVA and 5-HIAA did show increasing levels in con-
secutive CSF fractions. Since MHPG readily passes the blood-brain
(Kessler et al., 1976), as well as the blood-CSF barrier (Kopin et al.,
1983), CSF MHPG levels might not correlate with central noradrenergic
metabolism (Kessler et al., 1976), possibly because of constant inﬂow
from the blood compartment (Faull et al., 1990; Sharma et al., 1994).
Moreover, HVA and 5-HIAA are removed from the CSF by diﬀusion,
bulk ﬂow of CSF and active transport mechanisms (reviewed in Spector
et al., 2015). This diﬀerence in clearance mechanisms between CSF
MHPG, HVA and 5-HIAA, might additionally explain the observed
diﬀerences in concentration gradient of these compounds. Furthermore,
a decrease in the C4 fraction was observed for HVA, 5-HIAA and MHPG,
as well as a reduction of MHPG levels in the C2 fraction. It should be
noted that the C2 fraction of each study subject had already been used
for determination of the standard AD biomarker panel, and that CSF
MHPG levels, contrary to HVA and 5-HIAA concentrations, were found
to decrease even after a single freeze-thaw cycle (Willemse et al., un-
published results). Nevertheless, it remains unclear why CSF MHPG,
HVA and 5-HIAA levels were reduced in the C4 fraction. In most other
studies reporting the existence of a RCG in CSF HVA and 5-HIAA con-
centrations, a larger total volume of CSF was collected (Blennow et al.,
1993; Malm et al., 1994; Sjöström et al., 1975). Thus, as the decrease in
CSF analyte levels occurs after the ﬁrst 7.5mL in our study, it is possible
that this reﬂects normal biological variation, of which the eﬀect could
have been less pronounced if larger, and most importantly, more frac-
tions had been collected. This might also account for the shallow slope
observed for all analyzed compounds in Fig. 3. Generally, our results
suggest that the presence of a RCG of monoaminergic metabolites such
as HVA and 5-HIAA, might indeed inﬂuence the comparison of these
compounds between distinct factorial groups. We therefore suggest that
investigators analyze the ﬁrst CSF fraction from all study participants,
so that the possible eﬀect of the RCG is avoided.
Lastly, we observed consistently higher CSF 5-HIAA levels in the AD
group versus non-AD/control participants. Diﬀerent factors might ac-
count for this apparent discrepancy with the existing literature, in
which predominantly lower or unchanged CSF 5-HIAA levels were
noted in AD patients versus controls (Blennow et al., 1992; Janssens
et al., 2018; Sjögren et al., 1998), and in which a negative correlation
was found between AD severity and brain 5-HT and 5-HIAA levels
(Rodriguez et al., 2012; Vermeiren et al., 2014). The most important
factor is probably the presence of non-AD dementia types, which might
also display disturbances in monoamine content, in the ‘control’ group.
In addition, the individual dementia stage of the patients at the moment
of CSF collection, might also have inﬂuenced our ﬁndings.
4.3. Strengths, limitations and relevance
All analyses for the study of circadian rhythm were performed on a
valuable and extensive dataset incorporating paired CSF and plasma
samples derived from eight healthy volunteers, during a 30-h period. It
should be noted, however, that only seven subjects completed the
whole protocol, possibly decreasing statistical power. Samples were
thawed twice beforehand, which might have impacted our results as
freeze/thaw cycles could aﬀect the stability of monoaminergic com-
pounds. However, it has been demonstrated that CSF HVA and 5-HIAA
remain relatively stable even after six freeze-thaw cycles of variable
duration (Strawn et al., 2001; Willemse et al., unpublished results). In
addition, plasma melatonin levels were previously found to be un-
changed after three freeze/thaw cycles (Graham et al., 1998). The re-
sults of the linear mixed model analysis were concordant with the cir-
cadian rhythm ﬁndings, illustrated by the fact that the individual
acrophases corresponded with sampling time 14, which was the only
time point at which plasma melatonin levels diﬀered signiﬁcantly
compared to almost all other time points. Therefore, another strength of
this study can be found in the relatively accurate estimation of diurnal
melatonin rhythm. On the one hand, the long sampling intervals during
the night might have hampered an even more meticulous evaluation of
the circadian rhythm of all compounds, as the acrophases of all diurnal
compounds occurred during these four-hour intervals. On the other
hand, the circadian rhythm might have been disturbed if the subjects
were woken up more frequently during the night for sampling purposes.
Furthermore, as the circadian rhythm of melatonin is widely accepted
to occur around 02:00–04:00 h (Cajochen et al., 2003; Zeitzer et al.,
2007; Zhdanova et al., 1998; Zisapel, 2018), our results corroborated
these previous ﬁndings. Thus, melatonin could be considered a positive
Fig. 3. Concentrations of MHPG, HVA and 5-HIAA in each CSF fraction (panels A, B, and C, respectively). In A and B, the combined results of the non-AD/CONTR
group and the AD group are displayed, since no interaction eﬀect was found for either MHPG or HVA. In case of 5-HIAA, the results are depicted separately for each
diagnostic category. Statistically signiﬁcant post-hoc diﬀerences between CSF fractions after Bonferroni correction, are indicated by one (P < 0.05) or two
(P < 0.001) asterisks. Abbreviations: 5-HIAA: 5-hydroxyindoleacetic acid; AD: Alzheimer's disease; CONTR: control; CSF: cerebrospinal ﬂuid; HVA: homovanillic
acid; MHPG: 3-methoxy-4-hydroxyphenylglycol.
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control compound in this circadian rhythm study.
Concerning the investigation of the RCG, the use of CSF samples
derived from subjects who underwent neuropsychological assessment
and CSF biomarker analysis, increased the reliability of our results.
Moreover, storage- and handling conditions were similar across all
samples, thereby minimally aﬀecting diﬀerences between groups or
CSF fractions. However, the disease state of our study subjects has not
been conﬁrmed neuropathologically, and the sample size used for this
investigation was rather small, so that the eﬀect of a possible RCG on
monoaminergic metabolites might have been more pronounced if more
subjects were included in the analysis.
This work focuses on the methodological aspects of neurochemical
(biomarker) studies investigating monoamines and/or their metabo-
lites. These compounds are especially of interest since they were pre-
viously found to be altered in several forms of dementia (Aerts et al.,
2011; Herbert et al., 2014; Janssens et al., 2018; Parnetti et al., 1992;
Sjögren et al., 1998; Vermeiren et al., 2016) and since currently, most
of the available treatment options are associated with a lack of eﬃ-
ciency and/or important side eﬀects. Therefore, the assessment of al-
terations in these compounds should be free of misinterpretation and/
or bias due to the circadian rhythm and the RCG, so that monoamines/
metabolites can be identiﬁed as reliable biomarkers and/or therapeutic
targets in dementia.
5. Conclusions
In general, pre-analytical factors should be carefully considered
before the onset of studies investigating (monoaminergic) compounds
in biological ﬂuids. Despite relatively small study populations in this
work, we found that plasma HVA levels vary according to a circadian
rhythm similar to that of melatonin, which could be explained by a
shared control mechanism in the SCN. Our results indicated that plasma
and CSF should ideally be sampled in the early afternoon for the ana-
lysis of monoamines and their metabolites. Lastly, since a RCG was
observed for CSF HVA and 5-HIAA, it is advisable to standardize the
number and volume of CSF samples, so that comparable biological
specimens can be analyzed in future studies. To avoid confounding
eﬀects of the RCG, we propose to analyze the ﬁrst 1.5mL of CSF col-
lected in all study participants.
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